<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arcturus Therapeutics Holdings Inc — News on 6ix</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc</link>
<description>Latest news and press releases for Arcturus Therapeutics Holdings Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arcturus-therapeutics-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835479878dffbe2df0e377b.webp</url>
<title>Arcturus Therapeutics Holdings Inc</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc</link>
</image>
<item>
<title>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-to-report-first-quarter-financial-results-and-provide-corporate-update-on-may-7-2026</guid>
<pubDate>Mon, 27 Apr 2026 20:01:00 GMT</pubDate>
<description>SAN DIEGO, April 27, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.</description>
</item>
<item>
<title>Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and-pipeline-progress</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and-pipeline-progress</guid>
<pubDate>Tue, 03 Mar 2026 21:01:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates.</description>
</item>
<item>
<title>Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-fourth-quarter-210100767</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-fourth-quarter-210100767</guid>
<pubDate>Tue, 17 Feb 2026 21:01:00 GMT</pubDate>
<description>SAN DIEGO, February 17, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March</description>
</item>
<item>
<title>Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-present-44th-annual-223000236</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-present-44th-annual-223000236</guid>
<pubDate>Thu, 08 Jan 2026 22:30:00 GMT</pubDate>
<description>SAN DIEGO, January 08, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time.</description>
</item>
<item>
<title>Arcturus Therapeutics to Attend Upcoming Investor Conference</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-attend-upcoming-investor-conference-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-attend-upcoming-investor-conference-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-third-quarter-2025-financial-update-and-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-third-quarter-2025-financial-update-and-pipeline</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Encouraging CF interim Phase 2 data support continued and expanded trial design 12-week safety and preliminary efficacy study in up to 20 CF participants</description>
</item>
<item>
<title>Arcturus Therapeutics to Attend Upcoming Investor Conferences</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-attend-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-attend-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-third-quarter-financial-results-and-provide-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-third-quarter-financial-results-and-provide-corporate</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines</description>
</item>
<item>
<title>Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-provides-interim-phase-2-data-cystic-fibrosis-cf-program-2025</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-provides-interim-phase-2-data-cystic-fibrosis-cf-program-2025</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with</description>
</item>
<item>
<title>Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-second-quarter-2025-financial-update-and-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-second-quarter-2025-financial-update-and-pipeline</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete</description>
</item>
<item>
<title>Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-second-quarter-financial-results-and-provide-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-second-quarter-financial-results-and-provide-corporate</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused</description>
</item>
<item>
<title>Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-positive-interim-phase-2-multiple-dose-data-ornithine</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-positive-interim-phase-2-multiple-dose-data-ornithine</guid>
<pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
<description>ARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range 15N-ureagenesis data provide first evidence of an mRNA</description>
</item>
<item>
<title>Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-host-key-opinion-leader-kol-presentation-arct-810-phase-2</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-host-key-opinion-leader-kol-presentation-arct-810-phase-2</guid>
<pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-first-quarter-2025-financial-update-and-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-first-quarter-2025-financial-update-and-pipeline</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025</description>
</item>
<item>
<title>Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-first-quarter-financial-results-and-provide-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-first-quarter-financial-results-and-provide-corporate</guid>
<pubDate>Tue, 22 Apr 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-receives-us-fda-fast-track-designation-starrr-mrna-vaccine</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-receives-us-fda-fast-track-designation-starrr-mrna-vaccine</guid>
<pubDate>Thu, 10 Apr 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company</description>
</item>
<item>
<title>Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2024-financial-update</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-announces-fourth-quarter-and-fiscal-year-2024-financial-update</guid>
<pubDate>Thu, 06 Mar 2025 05:00:00 GMT</pubDate>
<description>Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial</description>
</item>
<item>
<title>Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-present-leerinks-global-healthcare-conference-2025-2025-03-05</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-present-leerinks-global-healthcare-conference-2025-2025-03-05</guid>
<pubDate>Wed, 05 Mar 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/arcturus-therapeutics-report-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Mon, 24 Feb 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company</description>
</item>
<item>
<title>European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine</title>
<link>https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/european-commission-approves-csl-and-arcturus-therapeutics-kostaiver-first-self-0</link>
<guid isPermaLink="true">https://6ix.com/company/arcturus-therapeutics-holdings-inc/news/european-commission-approves-csl-and-arcturus-therapeutics-kostaiver-first-self-0</guid>
<pubDate>Fri, 14 Feb 2025 05:00:00 GMT</pubDate>
<description>- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months</description>
</item>
</channel>
</rss>